Pilot Trial of Adjuvant Paclitaxel Plus Estramustine in Resected High-Risk Prostate Cancer

The adjuvant use of paclitaxel and estramustine in resected high-risk prostate cancer patients is feasible and well tolerated. Adjuvant cytotoxic chemotherapy deserves further investigation with randomized studies.